{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T20:53:59Z","timestamp":1693342439128},"reference-count":52,"publisher":"Informa UK Limited","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Expert Review of Gastroenterology & Hepatology"],"published-print":{"date-parts":[[2007,10]]},"DOI":"10.1586\/17474124.1.1.145","type":"journal-article","created":{"date-parts":[[2008,3,5]],"date-time":"2008-03-05T15:42:06Z","timestamp":1204731726000},"page":"145-154","source":"Crossref","is-referenced-by-count":5,"title":["New drugs for hepatitis C virus"],"prefix":"10.1586","volume":"1","author":[{"given":"Paul J","family":"Pockros","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2014,1,10]]},"reference":[{"key":"CIT0001","first-page":"S3","volume":"36","year":"2002","journal-title":"Hepatology"},{"key":"CIT0002","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","volume":"358","author":"Manns","year":"2001","journal-title":"Lancet"},{"key":"CIT0003","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1056\/NEJM200012073432301","volume":"343","author":"Zeuzem","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"CIT0004","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJM200012073432302","volume":"343","author":"Heathcote","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"CIT0005","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2001.21747"},{"key":"CIT0006","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1111\/j.1572-0241.2004.30306.x","volume":"99","author":"Pockros","year":"2004","journal-title":"Am. J. Gastroenterol."},{"key":"CIT0007","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","volume":"347","author":"Fried","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"CIT0008","doi-asserted-by":"crossref","first-page":"346","DOI":"10.7326\/0003-4819-140-5-200403020-00010","volume":"140","author":"Hadziyannis","year":"2004","journal-title":"Ann. Intern. Med."},{"key":"CIT0009","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1053\/j.gastro.2004.01.014","volume":"126","author":"Shiffman","year":"2004","journal-title":"Gastroenterology"},{"key":"CIT0010","first-page":"278A","volume":"42","author":"Nelson","year":"2005","journal-title":"Hepatology"},{"key":"CIT0011","doi-asserted-by":"crossref","unstructured":"Zeuzem S, Benhamou Y, Bain Vet al.Antiviral response at week 12 following completion of treatment with albinterferon \u03b1 2b plus ribavirin in genotype 1, IFN-naive, chronic hepatitis C patients. Presented at:The 42nd Annual Meeting of the European Association for the Study of Liver.Barcelona, Spain, April 11\u201315, 2007.","DOI":"10.1016\/S0168-8278(07)62377-0"},{"key":"CIT0012","doi-asserted-by":"crossref","unstructured":"Novozhenov V, Zakharova N, Vinogradova Eet al.Phase 2 study of omega interferon alone or in combination with ribavirin in subjects with chronic hepatitis C genotype-1 infection. Presented at:The 42nd Annual Meeting of the European Association for the Study of Liver.Barcelona, Spain, April 11\u201315, 2007.","DOI":"10.1016\/S0168-8278(07)61609-2"},{"key":"CIT0013","unstructured":"Marcellin P, Lurie Y, Rodriguez-Torres Met al.The safety and efficacy of taribavirin plus pegylated interferon \u03b1-2a versus ribavirin plus pegylated interferon \u03b1-2a in therapy-na\u00efve patients infected with HCV: Phase 3 results. Presented at:The 42nd Annual Meeting of the European Association for the Study of Liver.Barcelona, Spain, April 11\u201315, 2007."},{"key":"CIT0014","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1002\/hep.21561","volume":"45","author":"Pockros","year":"2007","journal-title":"Hepatology"},{"key":"CIT0015","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s11901-004-0004-y","volume":"3","author":"Pockros","year":"2004","journal-title":"Curr. Hepatitis Rep."},{"key":"CIT0016","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.jhep.2005.04.009","volume":"43","author":"Ferenci","year":"2005","journal-title":"J. Hepatol."},{"key":"CIT0017","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/nature02099","volume":"426","author":"Lamarre","year":"2003","journal-title":"Nature"},{"key":"CIT0018","first-page":"233A","volume":"42","author":"Zeuzem","year":"2005","journal-title":"Hepatology"},{"key":"CIT0019","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2004.11.012"},{"key":"CIT0020","first-page":"1270","volume":"32","author":"Zeuzem","year":"2007","journal-title":"Gastroenterology"},{"key":"CIT0021","doi-asserted-by":"crossref","unstructured":"Preston RA, Alonso AB, Feely Wet al.SCH 503034, an oral HCV protease inhibitor, is well-tolerated in patients with varying degrees of hepatic impairment. Presented at:The 42nd Annual Meeting of the European Association for the Study of the Liver.Barcelona, Spain, April 11\u201315, 2007.","DOI":"10.1016\/S0168-8278(07)62143-6"},{"key":"CIT0022","first-page":"234A","volume":"42","author":"Reesink","year":"2005","journal-title":"Hepatology"},{"key":"CIT0023","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2006.07.013"},{"key":"CIT0024","doi-asserted-by":"crossref","unstructured":"Lawitz EJ, Rodriguez-Torres M, Muir Aet al.28 days of the hepatitis C protease inhibitor VX-950, in combination with peg-interferon-\u03b1 2a and ribavirin, is well-tolerated and demonstrates robust antiviral effects.Program and Abstracts of Digestive Disease Week.Los Angeles, CA, USA, May 20\u201325, 2006.","DOI":"10.1053\/j.gastro.2006.06.100"},{"key":"CIT0025","doi-asserted-by":"crossref","unstructured":"McHutchison JG, Everson GT, Gordon Set al.Results of an interim analysis of a Phase 2 study of telaprevir (VX-950) with peginterferon \u03b1-2a and ribavirin in previously untreated subjects with hepatitis C. Presented at:The 42nd Annual Meeting of the European Association for the Study of the Liver.Barcelona, Spain, April 11\u201315, 2007.","DOI":"10.1016\/S0168-8278(07)62384-8"},{"key":"CIT0026","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2007.02.037"},{"key":"CIT0027","doi-asserted-by":"crossref","unstructured":"Kempf DJ, Chen H-J, Yeung CMet al.Pharmacokinetic boosting of VX-950, an inhibitor of HCV protease, by co-dosing with ritonavir.Program and Abstracts of the 41st Annual Meeting of the European Association for the Study of Liver.Vienna, Austria, April 26\u201330, 2006.","DOI":"10.1016\/S0168-8278(06)80005-X"},{"key":"CIT0028","first-page":"232A","volume":"42","author":"O\u2019Brien","year":"2005","journal-title":"Hepatology"},{"key":"CIT0029","first-page":"4","volume":"130","author":"Pockros","year":"2006","journal-title":"Gastroenterology"},{"key":"CIT0030","first-page":"23A","volume":"44","author":"Dieterich","year":"2006","journal-title":"Hepatology"},{"key":"CIT0031","unstructured":"Afdhal N, O\u2019Brien C, Godofsky Eet al.Valopicirabine (NM283), alone or with peginterferon, compared to peginterferon\/ribavirin treatment in patients with HCV-1 infection and prior non-response to peginterferon\/ribavirin: final results [Abstract].J. Hepatol.46(Suppl. 1) S5A (2007)."},{"key":"CIT0032","doi-asserted-by":"crossref","unstructured":"Roberts S, Cooksley G, Shaw Det al.Interim results of a multiple ascending dose study of R1626, a novel nucleoside analog targeting HCV polymerase in chronic HCV patients.Program and Abstracts of the 41st Annual Meeting of the European Association for the Study of the Liver.Vienna, Austria, April 26\u201330, 2006.","DOI":"10.1016\/S0168-8278(06)80731-2"},{"key":"CIT0033","unstructured":"Chandra P, Raible D, Harper D. Antiviral activity of the non-nucleoside polymerase inhibitor, HCV-796, in patients with chronic hepatitis C virus: preliminary results from a randomized, double-blind, placebo-controlled, ascending multiple dose study.Program and Abstracts of Digestive Disease Week.Los Angeles, CA, USA, May 20\u201325, 2006."},{"key":"CIT0034","doi-asserted-by":"crossref","unstructured":"Villano SA, Raible D, Harper Det al.Antiviral activity of the non-nucleoside polymerase inhibitor, HCV-796, in combination with pegylated interferon \u03b1-2b in treatment-na\u00efve patients with chronic HCV. Presented at:The 42nd Annual Meeting of the European Association for the Study of Liver.Barcelona, Spain, April 11\u201315, 2007.","DOI":"10.1016\/S0168-8278(07)61648-1"},{"key":"CIT0035","unstructured":"Ralston R, Howe AY, Chase Ret al.Favorable cross-resistance profile of HCV-796 and SCH-503034 and enhanced anti-replicon activity mediated by combination treatment. Presented at:Digestive Disease Week.Washington, DC, USA, May 19\u201324, 2007."},{"key":"CIT0036","doi-asserted-by":"crossref","unstructured":"Herrmann E, Flisiak R, Horban Aet al.Viral kinetics during 14-day treatment with DEBIO-025 demonstrate efficient blocking of viral replication in different HCV genotypes without signs of emerging viral resistance. Presented at:The 42nd Annual Meeting of the European Association for the Study of the Liver.Barcelona, Spain April 11\u201315, 2007.","DOI":"10.1016\/S0168-8278(07)61686-9"},{"key":"CIT0037","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2005.09.009"},{"key":"CIT0038","first-page":"788A","volume":"36","author":"Tong","year":"2002","journal-title":"Hepatology"},{"key":"CIT0039","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra045004"},{"key":"CIT0040","doi-asserted-by":"crossref","first-page":"7705","DOI":"10.1073\/pnas.0402458101","volume":"101","author":"Yu","year":"2004","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"CIT0041","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1093\/infdis\/173.4.822","volume":"173","author":"Drawczynski","year":"1996","journal-title":"J. Infect. Dis."},{"key":"CIT0042","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0168-8278(02)80095-2","volume":"36","author":"Willems","year":"2002","journal-title":"J. Hepatol."},{"key":"CIT0043","doi-asserted-by":"crossref","first-page":"701A","DOI":"10.1002\/hep.20947","volume":"42","author":"Schiano","year":"2005","journal-title":"Hepatology"},{"key":"CIT0044","first-page":"750A","volume":"42","author":"Di Bisceglie","year":"2005","journal-title":"Hepatology"},{"key":"CIT0045","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1016\/j.vaccine.2004.02.002","volume":"22","author":"Leroux-Roels","year":"2004","journal-title":"Vaccine"},{"key":"CIT0046","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1177\/095632020401500304","volume":"15","author":"Whitby","year":"2004","journal-title":"Antivir. Chem. Chemother."},{"key":"CIT0047","unstructured":"Dugourd Det al.Investigation of the synergistic interactions of the \u03b1-glucosidase I inhibitor celgosivir with various interferons. Presented at:The 13th International Meeting on Hepatitis C Virus and Related Viruses.Cairns, Australia, August 27\u201331, 2006."},{"key":"CIT0048","unstructured":"Yoshida E, Kunimoto D, Lee SSet al.Results of a Phase II dose ranging study of orally administered celgosivir as monotherapy in chronic hepatitis C genotype-1 patients.Program and Abstracts of Digestive Disease Week.Los Angeles, CA, USA, May 20\u201325, 2006."},{"key":"CIT0049","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21664"},{"key":"CIT0050","first-page":"75A","volume":"44","author":"McHutchison","year":"2006","journal-title":"Hepatology"},{"key":"CIT0051","unstructured":"Aspinall RJ, Pockros PJ. SCV-07 SciClone Pharmaceuticals \/Verta.Curr. Opin. Investig. Drugs7, 180\u2013185 (2006)"},{"key":"CIT0052","doi-asserted-by":"crossref","unstructured":"Pockros PJ, Patton H, Tong Met al.The results of 2 placebo-controlled, double-blind trials to determine the safety, tolerability and efficacy of an oral interferon inducer, Resiquimod, in chronic HCV.J. Hepatol.47, 174\u2013182 (2007).","DOI":"10.1016\/j.jhep.2007.02.025"}],"container-title":["Expert Review of Gastroenterology & Hepatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.tandfonline.com\/doi\/pdf\/10.1586\/17474124.1.1.145","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,8]],"date-time":"2019-05-08T17:47:18Z","timestamp":1557337638000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.tandfonline.com\/doi\/full\/10.1586\/17474124.1.1.145"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,10]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2014,1,10]]},"published-print":{"date-parts":[[2007,10]]}},"alternative-id":["10.1586\/17474124.1.1.145"],"URL":"https:\/\/doi.org\/10.1586\/17474124.1.1.145","relation":{},"ISSN":["1747-4124","1747-4132"],"issn-type":[{"value":"1747-4124","type":"print"},{"value":"1747-4132","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,10]]}}}